Dallas Territory Manager Files Retaliation Complaint
DALLAS — Eli Lilly faces a federal whistleblower lawsuit in Texas. A former sales manager filed it. The suit alleges wrongful termination tied to off-label drug marketing. Industry legal filings disclosed the case on November 11 and 12, 2026.
The complaint was filed in the Northern District of Texas. The case number is 3:26-cv-03924-N. Plaintiff Jennifer Mansion joined Eli Lilly's Dallas Diabetes Business Unit in October 2022. Her employment was terminated in November 2023. Mansion alleges she saw peers promote Mounjaro to medical clinics for obesity management. At the time, the therapy held FDA approval strictly for type 2 diabetes. Her filing also contends a speaker endorsed Mounjaro for weight reduction. That happened during a physician luncheon sponsored directly by the Indianapolis-based manufacturer.
Federal rules let licensed physicians prescribe approved medicines off-label. Drug manufacturers are legally barred from proactively marketing unapproved indications. Mansion stated she reported alleged promotional violations to her supervisor. She said she was told not to shy away from weight-loss benefits. The reason given: regulatory approval was anticipated soon. Mansion's complaint, submitted to the Texas federal district court, stated: "Despite her repeated objections, no changes were made to Eli Lilly's policy regarding the promotion of Mounjaro for off-label use, nor was anyone reprimanded for doing so." Eli Lilly spokesperson Jared Shapiro said company compliance standards prohibit off-label promotion.
Federal regulators later cleared tirzepatide for chronic weight management. It is the identical active molecular compound in Mounjaro. The commercial brand name is Zepbound. The clearance came roughly eighteen months after its initial diabetes authorization. Eli Lilly's third-quarter 2026 financial disclosures put Mounjaro worldwide sales at $29 billion year-to-date. Zepbound contributed an additional $14.4 billion. Combined, the two metabolic therapies account for 65 percent of Eli Lilly's total corporate revenue.
